 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| REGN9933 / Regeneron, REGN7508 / Regeneron
Enrollment open: Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants (clinicaltrials.gov) - Oct 9, 2024
P1, N=224, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting
- ||| REGN9933 / Regeneron, REGN7508 / Regeneron
Enrollment open: ROXI-CATH: A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (clinicaltrials.gov) - Oct 1, 2024
P2, N=195, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| REGN7508 / Regeneron
Trial completion: A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants (clinicaltrials.gov) - Oct 1, 2024
P1, N=80, Completed, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| REGN7508 / Regeneron
Enrollment open: ROXI-VTE II: A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (clinicaltrials.gov) - Jul 15, 2024
P2, N=180, Recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || REGN7508 / Regeneron
Enrollment closed: A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants (clinicaltrials.gov) - Jun 20, 2024
P1, N=80, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| REGN7508 / Regeneron
New P2 trial: ROXI-VTE II: A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (clinicaltrials.gov) - Jun 11, 2024
P2, N=180, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- ||| REGN9933 / Regeneron, REGN7508 / Regeneron
New P1 trial, Combination therapy: Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants (clinicaltrials.gov) - Jun 5, 2024
P1, N=224, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- |||| REGN9933 / Regeneron, REGN7508 / Regeneron
New P2 trial: ROXI-CATH: A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (clinicaltrials.gov) - Mar 7, 2024
P2, N=195, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- || REGN7508 / Regeneron
Trial completion date, Trial primary completion date: A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants (clinicaltrials.gov) - Feb 15, 2024
P1, N=80, Recruiting, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
- ||| REGN7508 / Regeneron
Enrollment open: A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants (clinicaltrials.gov) - Feb 1, 2023
P1, N=72, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024 Not yet recruiting --> Recruiting
- ||| REGN7508 / Regeneron
New P1 trial: A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants (clinicaltrials.gov) - Nov 2, 2022
P1, N=72, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals